Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tacrolimus |
Synonyms | |
Therapy Description |
Tacrolimus binds to FKBP-12 and inhibits calcineurin activity, resulting in immunosuppression (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tacrolimus | Hecoria | FK-506|Prograf|Advagraf | Tacrolimus binds to FKBP-12 and inhibits calcineurin activity, resulting in immunosuppression (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06287944 | Phase I | Melphalan Fludarabine Sirolimus 225Ac-DOTA-Daratumumab Tacrolimus | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT02251821 | Phase II | Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide | JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | Active, not recruiting | USA | 0 |
NCT01664910 | Phase Ib/II | Bendamustine + Fludarabine + Inotuzumab ozogamicin Rituximab anti-thymocyte globulin Tacrolimus | CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies | Completed | USA | 0 |
NCT01619761 | Phase I | Rituximab Fludarabine + Lenalidomide + Melphalan Mycophenolate mofetil Tacrolimus | Natural Killer (NK) Cells in Cord Blood Transplantation | Unknown status | USA | 0 |
NCT03913026 | Phase II | ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa | UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Active, not recruiting | CAN | 0 |
NCT02790515 | Phase II | Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim | Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | Active, not recruiting | USA | 0 |
NCT01701986 | Phase Ib/II | Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine | Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas | Completed | USA | 0 |
NCT01790568 | Phase II | Methotrexate Tacrolimus Vorinostat | Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant | Completed | USA | 0 |
NCT01685411 | Phase 0 | Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam | Busulfan and Cyclophosphamide Followed By ALLO BMT | Terminated | USA | 0 |
NCT02508038 | Phase I | Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa | Recruiting | USA | 0 |
NCT00857389 | Phase II | Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | Completed | USA | 0 |
NCT01621477 | Phase II | Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | Terminated | USA | 0 |
NCT01529827 | Phase II | Melphalan Methotrexate Tacrolimus Mycophenolate mofetil Fludarabine | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT01203722 | Phase Ib/II | Tacrolimus Sirolimus Cyclophosphamide + Fludarabine + Mycophenolate mofetil | Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | Recruiting | USA | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT03247088 | Phase Ib/II | Busulfan + Fludarabine + Sorafenib Cyclophosphamide Tacrolimus Filgrastim | Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02333162 | Phase I | Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT04103879 | Phase II | ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil | US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia | Active, not recruiting | USA | NLD | 0 |
NCT01760655 | Phase II | Tacrolimus Cyclophosphamide + Fludarabine + Thiotepa Mycophenolate mofetil | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | Completed | USA | 0 |
NCT00513474 | Phase I | Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01338987 | Phase II | Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | Completed | USA | 0 |
NCT01823198 | Phase Ib/II | Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim | Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies | Completed | USA | 0 |
NCT01256398 | Phase II | Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Completed | USA | 0 |